logo
Share SHARE
FONT-SIZE Plus   Neg

Pharmacyclics Turns To Profit In Q1 - Quick Facts

Pharmacyclics Inc. (PCYC) reported that its first-quarter GAAP net income was $75.6 million, or $1.02 per share, compared to GAAP net loss of $14.5 million, or $0.21 loss per share in the year ago quarter.

The non-GAAP net income for the fiscal quarter was $78.8 million or $1.06 income per share, compared to a non-GAAP net loss of $12.4 million, or $0.18 per share last year.

Revenue for the quarter was $102.7 million, compared to $37,000 last year, an increase of approximately $102.7 million.

Revenue for the latest quarter consisted primarily of $100 million of license and milestone revenue due to the Company's achievement of two clinical milestones in connection with the Company's collaboration and license agreement with Janssen Biotech, Inc.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.75 per share on revenues of $87.64 million for the quarter. Analysts' estimates typically exclude special items.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Alteryx, Inc., a provider of self-service data analytics software, is the latest tech company to go public in March. Alteryx said it has priced its IPO of 9 million shares of its Class A common stock at $14 per share, at the top end of its range of $12 to $14 per share. Dunkin' Donuts is bidding adieu to one of its frozen coffee beverages this summer. However, loyal fans of the decades-old menu staple have not taken kindly to the news. The coffee chain said it will discontinue its popular Coffee Coolatta beverage this summer and instead, introduce the new Frozen Dunkin' Coffee, made with coffee extract, sugar and milk. Canadian pipeline operator Enbridge Inc. said it will cut about 1,000 jobs, or six percent of its workforce, following the completion of its acquisition of Houston-based Spectra Energy Corp. The job cuts will take place across the merged company.
comments powered by Disqus
Follow RTT